Full Transparency

How the Kamura Score Works

A transparent, composite scoring system calculated from 4 weighted factors. No sponsorships. No pay-to-rank. Just data.

The Formula

Kamura Score = (Research × 0.45) + (Safety × 0.25) + (Access × 0.15) + (Value × 0.15)

The Four Factors

🔬

Research Evidence

45% weight

Clinical trial quantity & quality, study design (RCT > observational), meta-analyses, consistency of results, and replication.

Data sources: PubMed, Cochrane Library, clinical trial registries

90-100Multiple meta-analyses, 20+ RCTs, FDA approved for indication

70-89Several RCTs, consistent results, some meta-analyses

50-69Mix of RCT and observational, generally positive

30-49Primarily animal studies, few human trials

0-29Case reports only or no published research

🛡️

Safety Profile

25% weight

Side effect frequency & severity, drug interactions, contraindications, long-term safety data, and FDA/regulatory status.

Data sources: Clinical databases, community adverse event reports, FDA/EMA

90-100Minimal side effects, no serious adverse events, long safety track record

70-89Minor side effects, manageable, good safety data

50-69Moderate side effects, some caution needed, monitoring required

30-49Significant side effects, interactions, requires close monitoring

0-29Serious adverse events reported, high risk profile

🌐

Accessibility

15% weight

Available in UAE/globally, prescription requirements, ease of administration (oral > injectable), and provider network density.

Data sources: Clinic directories, pharmacy databases, community reports

90-100OTC, widely available, no prescription, easy to use

70-89Available with minor barriers, some regions restricted

50-69Prescription required, moderate availability

30-49Limited availability, complex administration

0-29Extremely restricted, not available in most markets

💰

Value for Money

15% weight

Monthly cost relative to effectiveness, cost per meaningful outcome, insurance coverage, and cost trends.

Data sources: Community price reports, clinic pricing, pharmacy pricing

90-100<$50/month, high effectiveness ratio

70-89$50-150/month, good effectiveness ratio

50-69$150-500/month, moderate effectiveness ratio

30-49$500-1000/month, questionable effectiveness ratio

0-29>$1000/month or very poor effectiveness ratio

Score Tiers

Gold Standard85-100Strong evidence + excellent safety + good accessibility and value

Strong70-84Solid evidence with good safety profile

Promising50-69Emerging evidence or mixed results, worth monitoring

Limited30-49Weak evidence or significant concerns

Insufficient0-29No meaningful evidence or actively harmful

Evidence Level Tags

Each treatment is scored globally (Kamura Score) but also graded per-outcome, because a treatment may be excellent for one use and limited for another.

Strong10+ RCTs, consistent results, meta-analysis available

Moderate5-10 studies or mix of RCTs and observational, generally consistent

Emerging2-5 studies, primarily animal models or small human trials

Limited1-2 studies, case reports, or purely observational

AnecdotalCommunity reports only, no formal research

Per-Outcome Grading (A-F)

Each treatment's outcomes are individually graded from A to F. For example, BPC-157 scores A for gut healing but C for neuroprotection — because real science is nuanced.

Strong evidence, consistent results

Good evidence, mostly positive

Emerging or mixed evidence

Weak evidence, limited data

No evidence or negative

Our Commitment

No sponsored rankings. No treatment manufacturer or clinic can pay to improve their Kamura Score. Rankings are calculated purely from data.

Full transparency. Every sub-score is visible. You can see exactly why a treatment scores the way it does. We show what works AND what doesn't.

Regular updates. Scores are updated as new research is published and real-world data grows. We continuously review new clinical trials, safety reports, and pricing changes.

Corrections welcome. If you believe a score is inaccurate, contact us with evidence and we'll review. Our methodology is open to scrutiny.

Explore the Treatment Index